These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10170294)

  • 21. A cultural and global perspective of United States health care economics.
    Williams TR
    Semin Radiat Oncol; 2008 Jul; 18(3):175-85. PubMed ID: 18513627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving success: assessing the role of and building a business case for technology in healthcare.
    Neumann CL; Blouin AS; Byrne EM
    Front Health Serv Manage; 1999; 15(3):3-28. PubMed ID: 10346251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of biotechnology-based healthcare products for prioritization in Indian context.
    Visalakshi S; Mohan S
    Int J Technol Assess Health Care; 2002; 18(3):718-27. PubMed ID: 12391962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biopharmaceuticals in China.
    Hu X; Ma Q; Zhang S
    Biotechnol J; 2006 Nov; 1(11):1215-24. PubMed ID: 17089435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotech pharmaceuticals and biotherapy: an overview.
    Steinberg FM; Raso J
    J Pharm Pharm Sci; 1998; 1(2):48-59. PubMed ID: 10945918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biopharmaceuticals derived from genetically modified plants.
    Goldstein DA; Thomas JA
    QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P & T Committee response to evolving technologies: preparing for the launch of high-tech, high-cost products. Roundtable discussion.
    Seltzer JL; Wordell CJ; Nash D; Johnson NE; Gottlieb JE
    Hosp Formul; 1992 Apr; 27(4):379-80, 386-92. PubMed ID: 10117768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [From orthoclone to denosumab, the fast growing market of monoclonal antibodies].
    Biot J; Fasano C; Dos Santos C
    Med Sci (Paris); 2009 Dec; 25(12):1177-82. PubMed ID: 20035702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trials of gene/biotechnology products.
    Röthig HJ
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):539-44. PubMed ID: 7885081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biotechnology: a special case for health technology assessment?
    Mason J; Drummond M
    Health Policy; 1997 Jul; 41(1):73-81. PubMed ID: 10169063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of biotechnology in pharmaceutical drug design].
    Gaisser S; Nusser M
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):732-7. PubMed ID: 21147436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. When the price is right.
    Nat Biotechnol; 2006 May; 24(5):473. PubMed ID: 16680108
    [No Abstract]   [Full Text] [Related]  

  • 35. Monoclonal antibodies market.
    Reichert J; Pavolu A
    Nat Rev Drug Discov; 2004 May; 3(5):383-4. PubMed ID: 15152631
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.
    Thwaites R; Townsend RJ
    Pharmacoeconomics; 1998 Feb; 13(2):175-80. PubMed ID: 10178645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic monoclonal antibody market.
    Ecker DM; Jones SD; Levine HL
    MAbs; 2015; 7(1):9-14. PubMed ID: 25529996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Products of new biotechnologies.
    FDA Drug Bull; 1986 Nov; 16(2):19. PubMed ID: 2950012
    [No Abstract]   [Full Text] [Related]  

  • 39. Biologicals: new horizons in pharmaceutical development.
    Oldham RK
    J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
    [No Abstract]   [Full Text] [Related]  

  • 40. Challenges to the economic evaluation of new biotechnological interventions in healthcare.
    Mason J
    Pharmacoeconomics; 1999 Aug; 16(2):119-25. PubMed ID: 10539393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.